Peruvian health authorities have suspended clinical trials of the Corona 19 vaccine in Sinopharm, China. One of the participants showed signs of arm paralysis.
According to AFP on the 12th (local time), Peru's National Institutes of Health suspended clinical trials after one participant was unable to move his arm due to "Gillain-Barre syndrome." "One of the participants showed neurological symptoms equivalent to Gilean-Barre syndrome," a senior researcher at Peru's National Institutes of Health told a press conference the same day.
Gilean-Barre syndrome is a condition in which peripheral nerves are destroyed, causing pain and paralysis in the arms and legs. There is a precedent in which hundreds of people suffered from Gilean-Barre syndrome and at least 30 died among those who received a new flu vaccine developed during Ford's presidency in 1976.
Sinopharm said, "There have been more than 1 million people who have received our vaccine so far, but there has been <a href="https://www.allwin79.xyz">슬롯사이트주소</a> no side effect," adding that it plans to provide 1 billion doses by next year.
It is heard that Sinopharm is preparing for release in earnest while conducting transportation training in China. According to the state-run Global Times on the 11th, Sinopharm conducted a vaccine transportation exercise involving 40 storage, transportation and information companies in 31 provinces in China the previous day. On the same day, some Chinese provinces announced a series of vaccine use plans on the same day on the news that the launch of the Corona 19 vaccine was imminent.
Chinese experts say the Sinopharm Corona 19 vaccine is likely to be licensed and sold within this month.
댓글 없음:
새 댓글을 작성할 수 없습니다.